<DOC>
	<DOCNO>NCT01078116</DOCNO>
	<brief_summary>Evaluation Health Related Quality Life ( HRQL ) paramount importance assess impact rheumatoid arthritis patient ' health status , however cost associate rheumatoid arthritis also take account , information provide may lead balanced view analyze treatment disease . In accordance , main objective study evaluate impact adalimumab treatment patient ' Health Related Quality Life also cost disease management . In order accomplish study focus : 1 . Estimating direct indirect cost incur adalimumab treatment . 2 . Measuring Health Related Quality Life rheumatoid arthritis patient adalimumab treatment . 3 . Exploring cost-utility relationship rheumatoid arthritis patient treat adalimumab combine Health Related Quality Life rheumatoid arthritis patient direct well indirect cost due RA . More specifically , data relate patient ' Health Related Quality Life cost associate rheumatoid arthritis record one-year period , collect four subsequent visit : baseline , month 3 , 6 12 . The visit start treatment adalimumab consider baseline . This information use compare Health Related Quality Life cost data adalimumab initiation therefore identify effect adalimumab treatment patient rheumatoid arthritis .</brief_summary>
	<brief_title>Cost Utility Analyses Adalimumab Treatment Patients With Rheumatoid Arthritis ( RA )</brief_title>
	<detailed_description>Data concerning patient ' Health Related Quality Life well cost disease treatment collect four subsequent period specifically baseline ( Visit 1 ) , month 3 , 6 12 . Moreover , baseline patient ' socioeconomic , history illness data well use prescribed medication cost due rheumatoid arthritis record , order identify patient ' health state adalimumab treatment initiation . Patients discontinue therapy ( drop-outs ) either due adverse event initiative categorize analyzed separately , reason lead discontinuation record . Adverse event collect study exception adverse event lead withdrawal . In order evaluate cost-utility adalimumab cost disease treatment Health Related Quality Life rheumatoid arthritis patient take account . The process describe : Face-to-face interview conduct physicians/investigators charge four subsequent period well adalimumab treatment initiation . A questionnaire , divide follow section , administer : 1 . Patients ' Sociodemographic Characteristics 2 . Measurement Health Related Quality Life Rheumatoid Arthritis patient 3 . Cost Assessment</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Patients moderate severe active rheumatoid arthritis , prescribe receive adalimumab normal clinical practice least one month accord approve Summary Product Characteristics ( SmPC ) European Union . Patients must willing consent data collect provided Abbott Laboratories . Contraindications accord SmPC Patients participate observational Abbott study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>Rheumatoid Arthritis</keyword>
	<keyword>Adalimumab treatment</keyword>
	<keyword>Evaluation patient ' Health Related Quality Life</keyword>
	<keyword>Cost disease management</keyword>
</DOC>